Skip to main content

Table 3 Studies of immunotherapy in patients with EGFR ex20ins NSCLC

From: EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Treatment (reference) N Line ORR (%) mPFS (months) mOS (months)
ICI (monotherapy or combination therapy) [43] 15 ≥1 6.7 2.0 5.3
ICI monotherapy [44] 11 1 9.1 11.0 3.1
ICI + platinum agent [44] 16 1 18.8 11.3 4.5
ICI monotherapy [44] 32 ≥2 3.1 8.1 2.3
ICI + platinum agent [44] 20 ≥2 5 7.1 2.2